Drug Details

General Information of the Drug (ID: DR2863)
Name
Procarbazine
Synonyms
procarbazine; 671-16-9; Procarbazin; Ibenzmethyzin; Natulan; Ibenzmethyzine; Procarbazin [German]; Procarbazina; Procarbazinum; Procarbazinum [INN-Latin]; Procarbazina [INN-Spanish]; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-; Ro 4-6467; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; CB 400-497; MIH; Procarbazine free base; UNII-35S93Y190K; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; PCX; Ro 4-6467/1; 671-16-9 (free base); Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-; CHEBI:71417; 35S93Y190K; CB 400-497; Ibenzmethyzine; MIH; p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-; Procarbazine [INN:BAN]; 4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide; Procarbazine (INN); CCRIS 2389; HSDB 3250; NCGC00016438-01; Ro-4646711; CAS-366-70-1; EINECS 211-582-2; p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; BRN 0958270; SR-01000763375; Procarbazine-[d3]; p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-; SRI-10847; MBH (Salt/Mix); Matulane (Salt/Mix); Nathulane (Salt/Mix); Natunalar (Salt/Mix); Prestwick0_001112; Prestwick1_001112; Prestwick2_001112; Prestwick3_001112; DSSTox_CID_1189; SCHEMBL4656; CHEMBL1321; DSSTox_RID_75999; NCIOpen2_004074; DSSTox_GSID_21189; BSPBio_001244; BIDD:GT0183; SPBio_003112; BPBio1_001369; GTPL7278; DTXSID4021189; 4-[(2-methylhydrazinyl)methyl]-N-(propan-2-yl)benzamide; HMS2090J09; Pharmakon1600-01502326; RO-4-6467 FREE BASE; BCP12198; Tox21_301738; 0319AC; NSC759626; STL483417; ZINC19166988; AKOS015891211; AC-4547; CCG-213031; DB01168; MCULE-9065058360; NSC-759626; NCGC00016438-02; NCGC00016438-05; NCGC00255280-01; CAS-671-16-9; NCI60_041703; Ro-4-6467/1; SRI-10847-09; SRI-10847-10; SRI-10847_11; SRI-10847_13; DB-082065; RO-4-6467; FT-0737820; C07402; D08423; 671P169; Q418656; N-Isopropyl-.alpha.-(2-methylhydrazino)-p-toluamide; SR-01000763375-3; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide #; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hodgkin lymphoma [ICD-11: 2B30] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption
The drug is rapidly and completely absorbed
Half-life
The concentration or amount of drug in body reduced by one-half in 10 minutes
Metabolism
The drug is metabolized via the liver
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 27.11194 micromolar/kg/day
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C12H19N3O
PubChem CID
4915
Canonical SMILES
CC(C)NC(=O)C1=CC=C(C=C1)CNNC
InChI
1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
InChIKey
CPTBDICYNRMXFX-UHFFFAOYSA-N
CAS Number
CAS 671-16-9
ChEBI ID
CHEBI:71417
TTD Drug ID
D08GYO
DrugBank ID
DB01168
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vinblastine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination.
Target and Pathway
Target(s) Human Deoxyribonucleic acid (hDNA)  Molecule Info  [3]
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7278).
Reference 2 The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination. Cancer Treat Rev. 1979 Jun;6 Suppl:107-13.
Reference 3 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
 Download Picture         KEGG Link